ClinicalTrials.Veeva
Menu

Find clinical trials for Ovarian Cancer in Salt Lake City, UT

CTV is a public benefit provided by Veeva Systems to help you find the most relevant clinical trials for you and your loved ones

Related conditions:

Ovarian Epithelial Carcinoma
Endometrial Cancer
Cancer
Breast Cancer
Fallopian Tube Cancer
Non-Small-Cell Lung Carcinoma
Triple Negative Breast Cancer

Ovarian Cancer trials near Salt Lake City, UT, USA:

Trial of NP-G2-044 (Prilukae) Combined With PLD for Treatment of Platinum-Resistant Ovarian Cancer (ULTIMUS-1)

liposomal doxorubicin (PLD), and to compare the efficacy and safety of NP-G2-044+PLD vs. PLD alone in participants with platinum-resistant ovarian...

Enrolling
Platinum-resistant Ovarian Cancer
Drug: NP-G2-044
Drug: PLD

Phase 2, Phase 3

Novita Pharmaceuticals

Salt Lake City, Utah, United States and 4 other locations

A Study to Assess Adverse Events, Change in Disease Activity and How Intravenous (IV) ABBV901 Moves Through the Body Alone or in Combination With Bevacizumab in Adult Participants With Ovarian Cancer

Ovarian cancer (OC) is a lethal disease. The purpose of this study is to assess the safety, pharmacokinetics and efficacy of ABBV90 ...

Enrolling
Ovarian Cancer
Drug: ABBV-901
Drug: Bevacizumab

Phase 1

AbbVie
AbbVie

West Valley City, Utah, United States and 7 other locations

Durvalumab Treatment in Combination With Chemotherapy and Bevacizumab, Followed by Maintenance Durvalumab, Bevacizumab and Olaparib Treatment in Advanced Ovarian Cancer Patients (DUO-O)

followed by maintenance durvalumab and bevacizumab or durvalumab, bevacizumab and olaparib in patients with newly diagnosed advanced ovarian ...

Active, not recruiting
Advanced Ovarian Cancer
Drug: Bevacizumab
Drug: Durvalumab placebo

Phase 3

AstraZeneca
AstraZeneca

Salt Lake City, Utah, United States and 213 other locations

Ribociclib&Belinostat In Patients w Metastatic Triple Neg Breast Cancer & Recurrent Ovarian Cancer w Response Prediction By Genomics (CHARGE)

to the enrollment of patients diagnosed with triple-negative breast cancer or ovarian cancer. Dose expansion will only be ...

Enrolling
Recurrent Ovarian Carcinoma
Metastatic Breast Cancer
Drug: Belinostat
Drug: Ribociclib

Phase 1

Utah System of Higher Education (USHE)
Utah System of Higher Education (USHE)

Salt Lake City, Utah, United States and 1 other location

Study of Romiplostim for Chemotherapy-induced Thrombocytopenia in Adult Subjects With Non-small Cell Lung Cancer (NSCLC), Ovarian Cancer, or Breast Cancer

To evaluate the efficacy of romiplostim for the treatment of CIT in patients receiving chemotherapy for the treatment of NSCLC, ovarian cancer...

Active, not recruiting
Chemotherapy-induced Thrombocytopenia
Drug: Placebo
Drug: Romiplostim

Phase 3

Amgen
Amgen

Ogden, Utah, United States of America and 139 other locations

A Study to Learn if 27T51, a Mucin-16 (MUC16) Protein Targeting Immune Cell Therapy, Administered Alone or in Combination is Safe and How Well it Works for Adult Participants With Recurrent or Treatment Resistant Ovarian Cancers

help researchers understand more fully whether this immune cell therapy, also known as CAR T cell therapy, can be safely used to treat solid tumors...

Enrolling
Epithelial Ovarian Cancer
Fallopian Tube Cancer
Drug: Cemiplimab
Other: 27T51

Phase 1

Regeneron Pharmaceuticals
Regeneron Pharmaceuticals

Salt Lake City, Utah, United States and 4 other locations

A Clinical Study of Raludotatug Deruxtecan in People With Ovarian Cancer (MK-5909-003)

Researchers are looking for other ways to treat relapsed high-grade serous ovarian cancer. Relapsed means the cancer came ...

Enrolling
Ovarian Cancer Recurrent
Biological: Pembrolizumab
Biological: Bevacizumab

Phase 1, Phase 2

Merck Sharp & Dohme (MSD)
Merck Sharp & Dohme (MSD)

West Valley City, Utah, United States and 15 other locations

Locations recently updated

A Study of Avutometinib (VS-6766) + Defactinib (VS-6063) in Recurrent Low-Grade Serous Ovarian Cancer (RAMP 301)

This study will assess the safety and efficacy of avutometinib (VS-6766) in combination with defactinib versus Investigator's choice of treatments (I...

Enrolling
Low Grade Serous Ovarian Cancer
Drug: Defactinib
Drug: Letrozole

Phase 3

Verastem

Murray, Utah, United States and 105 other locations

A Study of INCB123667 in Participants With Platinum-Resistant Ovarian Cancer With Cyclin E1 Overexpression (MAESTRA 1)

This study will evaluate the safety and efficacy of INCB123667 in Participants With Platinum-Resistant Ovarian Cancer (PROC) With C...

Enrolling
Ovarian Cancer
Drug: INCB123667

Phase 2

Incyte
Incyte

Salt Lake City, Utah, United States and 79 other locations

A Comparison of Platinum-based Therapy With TSR-042 and Niraparib Versus Standard of Care (SOC) Platinum-based Therapy as First-line Treatment of Stage III or IV Nonmucinous Epithelial Ovarian Cancer (FIRST)

Ovarian cancer is a heterogeneous disease, characterized by complex molecular and genetic changes. The high expression of vascular ...

Active, not recruiting
Ovarian Neoplasms
Ovarian, Fallopian Tube and Primary Peritoneal Carcinoma
Drug: Dostarlimab-Placebo
Drug: Standard of care

Phase 3

Tesaro
Tesaro

Ogden, Utah, United States and 181 other locations

Clinical trials

Find clinical trialsTrials by location

Research sites

Find research sitesLearn about CTV for professionals

Resources

Contact CTV support

Legal

Privacy NoticeTerms
© Copyright 2026 Veeva Systems